CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.
Pain is a negative feeling associated with damage to the body’s tissues and it is crucial to survival. Putting a hand on a very hot object “feels bad” and that negative feeling rapidly teaches even very young children not to do that again. This sort of acute pain that resolves when the damage stops makes perfect evolutionary sense.Read more
Treatment of neuropathic pain is still a clearly unmet medical need. There are no pain medicines which have universal efficacy and most partially effective drugs have unwanted morphine-like side effects.Read more
Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.Read more
PharmNovo appoints CFO and Clinical lead to strengthen the organization.Read more
We are pleased to inform that during the summer, the application to startRead more